Results 61 to 70 of about 5,736 (192)

Efficacy and safety of deferiprone (Ferriprox), an oral iron-chelating agent, in pediatric patients [PDF]

, 2010
BACKGROUND: Iron overload is a predictable and life-threatening complication in patients dependent on the regular transfusion of RBCs. The aims of this study were to investigate the efficacy and safety of deferiprone in a variety of pediatric hematologic
유철주, 원성철
core   +1 more source

Co‐pathologies and biological processes beyond amyloid‐beta and tau in people with Alzheimer's disease: Evidence from clinical cohort studies

Journal of Internal Medicine, Volume 299, Issue 6, Page 694-710, June 2026.
Abstract Alzheimer's disease (AD) is neuropathologically defined by amyloid‐beta (Aβ) plaques and tau neurofibrillary tangles. However, co‐pathologies and other pathobiological processes are involved in the pathogenesis of AD, contributing to neurodegeneration and clinical symptoms.
Daniel Ferreira, Tomasz Chmiela, Maria Eriksdotter, Clifford R. Jack Jr., Grégoria Kalpouzos, Anna Marseglia, Patrizia Mecocci, Agneta Nordberg, Dorota Religa, Eric Westman   +9 more
wiley   +1 more source

A Patient with Beta-Propeller Protein-Associated Neurodegeneration: Treatment with Iron Chelation Therapy [PDF]

Journal of Movement Disorders, 2018
We present a case of beta-propeller protein-associated neurodegeneration, a form of neurodegeneration with brain iron accumulation. The patient harbored a novel mutation in the WDR45 gene.
Shen-Yang Lim, Ai Huey Tan, Azlina Ahmad-Annuar, Susanne A. Schneider, Ping Chong Bee, Jia Lun Lim, Norlisah Ramli, Mohamad Imran Idris   +7 more
doaj   +1 more source

Metal‐Free and Solvent‐Free CO2 Fixation Into Cyclic Carbonates Catalyzed by a Deferiprone‐Derived Bifunctional System

European Journal of Organic Chemistry, Volume 29, Issue 20, 27 May 2026.
A simple bifunctional organocatalyst derived from the FDA‐approved chelator deferiprone efficiently promotes CO2 fixation into cyclic carbonates. By combining epoxide activation and nucleophilic ring opening in a single scaffold, quantitative conversions are achieved under mild, metal‐free conditions. High activity, broad substrate scope, and excellent
Erika Saccullo, Luca Calantropo, Roberto Fiorenza, Pietro Nicotra, Antonio Rescifina, Vincenzo Patamia, Giuseppe Floresta   +6 more
wiley   +1 more source

Restoring Iron Homeostasis via Smoothened Inhibition: A Novel Strategy Against Hearing Loss

Advanced Science, Volume 13, Issue 29, 22 May 2026.
 . ABSTRACT Sensorineural hearing loss (SNHL) induced by noise or aminoglycoside antibiotics is a significant public health concern without any FDA‐approved pharmaceutical therapies. Dysregulation of iron homeostasis and its subsequently induced ferroptosis has increasingly been identified as a key mechanism underlying cochlear hair cell (HC) damage ...
Huanyu Mao, Xiang Li, Yaqi Liao, Liman Liu, Xian Gao, Hailiang Lin, Wenli Ni, Huawei Li, Yan Chen, Wenyan Li   +9 more
wiley   +1 more source

Solubility data of deferiprone in propylene glycol and 1-propanol mixtures at 293.2–323.2 K

Chemical Thermodynamics and Thermal Analysis
Experimental determination on solubility of deferiprone in propylene glycol + 1-propanol mixtures and their saturated solution's densities were reported at atmospheric pressure (101 kPa) from 293.2 to 313.2 K.
Homa Rezaei, Elaheh Rahimpour, Abolghasem Jouyban   +2 more
doaj   +1 more source

Single‐nucleus RNA sequencing reveals ferroptosis as a potential contributor to the pathogenesis of focal cortical dysplasia

Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.
1. A single‐cell analysis was conducted to investigate the transcriptomic changes in cells within focal cortical dysplasia (FCD). 2. Ferroptosis may play a significant role in the pathogenesis of FCD, potentially contributing to cellular damage and epileptogenesis. 3.
Qingyang Zeng, Fengjun Zhu, Dezhi Cao, Yang Sun, Lin Li, Zeshi Tan, Cong Li, Xiaofan Ren, Yidi Liu, Zhiqiang Lin, Dongfang Zou   +10 more
wiley   +1 more source

The optimization of iron chelation with deferiprone

, 1997
grantor: University of TorontoDeferiprone is an orally active iron-chelating agent that reduces the body iron burden of chronically transfused, iron-overloaded homozygous beta-thalassemia patients.
Fassos, Frank Fotios
core  

Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major

, 2006
Deferoxamine (DFO) therapy has been associated with improved survival of thalassemia patients. However, cardiac disease remains the main cause of death in those patients. In 1995, the oral chelator deferiprone became available for clinical use.
M. A. Romeo, M. D. Cappellini, C. Borgna Pignatti, G. L. Forni, P. De Stefano, BORGNA, Caterina, G. C. Del Vecchio, R. Ghilardi, M. R. Gamberini, A. Cnaan, M.D. Cappellini, A. Piga, H. Zhao   +12 more
core   +1 more source

Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration

Frontiers in Molecular Neuroscience, 2018
There is an emerging link between the accumulation of iron in the brain and abnormal tau pathology in a number of neurodegenerative disorders, such as Alzheimer’s disease (AD).
Shalini S. Rao, Paul Anthony Adlard
doaj   +1 more source